Here are the Form 4 insider transactions from Elite Pharms Inc (ELTP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTP filings page.
Elite Pharmaceuticals Inc. (ELTP) director Barry H. Dash purchased 100,000 shares of common stock at $0.2598 per share on October 9, 2026. The shares were held directly, and he reported 3,365,555 shares after the purchase. The form reports no Rule 10b5-1 plan.
ELITE PHARMACEUTICALS INC (ELTP) director Barry H Dash reported purchasing 30,000 shares of common stock on August 19, 2026, in a purchase described as an open market or private transaction at $0.287 per share.
After this buy, he directly owns 3,265,555 shares of ELTP common stock, and no Rule 10b5-1 plan is reported for this transaction.
Elite Pharmaceuticals executive Douglas Plassche reported an option exercise. On 01/09/2026, the EVP of Operations exercised stock options covering 2,500,000 shares of Elite Pharmaceuticals common stock at an exercise price of $0.03 per share, converting them into 2,500,000 shares of common stock.
The stock options were fully vested and exercisable as of the transaction date. Following this transaction, Plassche directly beneficially owns 6,000,000 shares of Elite Pharmaceuticals common stock and holds no remaining derivative securities from this reported option grant.